Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;29(2):156-165.
doi: 10.21147/j.issn.1000-9604.2017.02.09.

Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China

Heng Li  1 , Wenjie Xiong  1 , Huimin Liu  1 , Shuhua Yi  1 , Zhen Yu  1 , Wei Liu  1 , Rui Lyu  1 , Tingyu Wang  1 , Dehui Zou  1 , Zengjun Li  1 , Lugui Qiu  1
Affiliations

Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China

Heng Li et al. Chin J Cancer Res. 2017 Apr.

Abstract

Objective: This study aims to evaluate the natural history of patients with chronic lymphocytic leukemia (CLL) and a 17p deletion (17p-) and identify the predictive factors within this subgroup.

Methods: The sample of patients with CLL were analyzed by fluorescencein situ hybridization for deletions in chromosome bands 11q22, 13q14 and 17p13; trisomy of bands 12q13; and translocation involving band 14q32. The data from 456 patients with or without a 17p- were retrospectively collected and analyzed.

Results: The overall response rate (ORR) in patients with a 17p- was 56.9%, and patients with a high percentage of 17p- (defined as more than 25% of cells harbouring a 17p-) had a lower ORR. The median overall survival (OS) in patients with a 17p- was 78.0 months, which was significantly shorter than the OS in patients without this genetic abnormality (median 162.0 months, P<0.001). Within the subgroup with a 17p-, the progression-free survival was significantly shorter in patients at Binet stage B-C and patients with elevated lactate dehydrogenase (LDH), B symptoms, unmutatedIGHV and a high percentage of 17p-.

Conclusions: These results indicated that patients with a 17p- CLL have a variable prognosis that might be predicted using simple clinical and laboratory characteristics.

Keywords: 17p deletion; chronic lymphocytic leukemia (CLL); del17p in CLL; fluorescentin situ hybridization (FISH).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

1
1
Time to progression (TTP) and overall survival (OS) after first therapy. (A) Patients with a complete response (CR) experienced a significantly better TTP; (B) Patients with a CR experienced a significantly prolonged survival than patients with a partial response (PR) or patients with no response. Pa was calculated by Log-rank test; Pb was calculated by Cox regression test.
2
2
Impact on survival of 17p deletion (17p-) at different clonal size. Time to first treatment (A, D), progression-free survival (B, E) and overall survival (C, F) after CLL diagnosis were affected by 17p- clone size. Pa was calculated by Log-rank test; Pb was calculated by Cox regression test.
S1
S1
ROC curves of the 17p deletion clone size as regards disease progression (A) or deaths (B).
3
3
Progression-free survival according to (A) Binet stage Avs. B or C; (B) presencevs. absence of B symptoms; (C) elevatedvs. normal lactic dehydrogenase level; (D) mutatedvs. unmutated immunoglobulin heavy chain variable region (M-IGHVvs. U-IGHV); and (E) clone size of 17p deletion (17p-) (<25%vs. ≥25%).
See this image and copyright information in PMC

References

    1. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2013, National Cancer Institute. Bethesda, MD. Available online:

    1. Chihara D, Ito H, Matsuda T, , et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–45. [Chihara D, Ito H, Matsuda T, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 2014;164:536-45.] - PMC - PubMed
    1. Chen C, Puwada S. Prognostic factors for chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2016;11:37–42. [Chen C, Puwada S. Prognostic factors for chronic lymphocytic leukemia. Curr Hematol Malig Rep 2016;11:37-42.] - PubMed
    1. Döhner H, Stilgenbauer S, Benner A, , et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6. [Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.] - PubMed
    1. Döhner H, Fischer K, Bentz M, , et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580–9. [Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-9.] - PubMed

LinkOut - more resources